How will the October 2025 private placement by Samsara, RA Capital, and others impact institutional ownership?

Rani Therapeutics Holdings, Inc. (RANI) completed an oversubscribed private placement in October 2025, raising approximately $60.3 million. This financing event is expected to significantly impact institutional ownership by increasing the stakes of the participating institutional investors.1

Key details of the private placement include:

• Participants: The placement was led by Samsara BioCapital and included RA Capital Management, Anomaly, Special Situations Funds, and Invus, along with the company's founder and chairman, Mir Imran.1
• Securities Issued: RANI sold 42,633,337 shares of Class A Common Stock, common stock warrants to purchase up to 125,000,004 shares, and pre-funded warrants to purchase up to 82,366,667 shares.2
• Debt Conversion: Approximately $6.0 million of outstanding debt from Avenue Venture Opportunities Fund was converted into shares and warrants as part of the private placement.1
• Board Appointments: Concurrently with the private placement, Abraham Bassan (Partner at Samsara BioCapital) and Vasudev Bailey, Ph.D. (General Partner at Anomaly Ventures) were appointed to RANI's Board of Directors, signaling increased institutional involvement and oversight.1

This substantial issuance of shares and warrants directly to institutional investors means a considerable increase in their collective ownership percentage. The private placement proceeds, combined with a collaboration agreement with Chugai, are projected to extend RANI's cash runway into 2028, strengthening the company's financial position.1 This influx of capital and the strategic backing from prominent biotech investors could also attract further institutional interest in the company.

Research the historical investment patterns of Samsara BioCapital and RA Capital Management in similar biotech companies to contextualize their investment in RANI.